Pharmacometric Modeling of the Impact of Azelastine Nasal Spray on SARS-CoV-2 Viral Load and Related Symptoms in COVID-19 Patients

The histamine-1 receptor antagonist azelastine was recently found to impact SARS-CoV-2 viral kinetics in a Phase 2 clinical trial (CARVIN). Thus, we investigated the relationship between intranasal azelastine administrations and viral load, as well as symptom severity in COVID-19 patients and analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Dings, Christiane, Meiser, Peter, Holzer, Frank, Flegel, Michael, Selzer, Dominik, Nagy, Eszter, Mösges, Ralph, Klussmann, Jens Peter, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609097/
https://www.ncbi.nlm.nih.gov/pubmed/36297492
http://dx.doi.org/10.3390/pharmaceutics14102059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609097/
https://www.ncbi.nlm.nih.gov/pubmed/36297492
http://dx.doi.org/10.3390/pharmaceutics14102059

Ejemplares similares